Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The BCL-2 family is a group of evolutionarily conserved proteins that are central regulators of apoptosis, particularly the intrinsic (mitochondrial) pathway. This family includes both anti-apoptotic members such as BCL-2, BCL-xL, and Mcl-1, as well as pro-apoptotic members like Bax and Bak. The balance between these opposing factions determines cell fate in response to stress or developmental cues. Dysregulation—especially overexpression—of anti-apoptotic members like BCL‑2 is implicated in various cancers including follicular lymphoma due to chromosomal translocations such as t(14;18). Overexpression leads to resistance against programmed cell death—a hallmark of cancer progression. Therapeutic targeting with small-molecule inhibitors ("BH3 mimetics") has shown promise in hematological malignancies by restoring apoptotic sensitivity. Mcl‑1 is essential for survival across multiple immune cell types including T lymphocytes at various developmental stages.
Inhibition of anti-apoptotic proteins, activation of pro-apoptotic proteins, promotion of cytochrome c release from mitochondria
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell lymphoma protein 2 family proteins (BCL-2 family).